Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia

This study has been completed.
Sponsor:
Information provided by:
Henry Ford Health System
ClinicalTrials.gov Identifier:
NCT00294502
First received: February 21, 2006
Last updated: NA
Last verified: September 2003
History: No changes posted
  Purpose

To study the efficacy of an antibacterial/anticoagulant solution instilled into the hemodialysis (HD) catheters after each treatment (“antibiotic lock solution - ALS”) to prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.


Condition Intervention Phase
ESRD
Drug: Gentamycin/citrate, Minocycline/EDTA
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Henry Ford Health System:

Primary Outcome Measures:
  • Incidence of symptomatic CRB

Estimated Enrollment: 120
Study Start Date: September 2003
Estimated Study Completion Date: May 2004
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • ESRD patients with tunnelled catheters

Exclusion Criteria:

  • patients on IV abx for infections, patients who have AV graft, AV fistulas
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00294502

Locations
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Investigators
Principal Investigator: Antanole Bearabe, MD Henry Ford Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00294502     History of Changes
Other Study ID Numbers: 3008
Study First Received: February 21, 2006
Last Updated: February 21, 2006
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Gentamicins
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 29, 2014